IN THE CLAIMS:

Please rewrite claim 16 as shown below in the detailed listing of all claims which are, or were, in the application:

Claims 1-10 (canceled).

11. (Previously presented) A method for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or an animal, wherein an effective amount of a pharmaceutically acceptable agent or salt thereof being able to acidify cell cytoplasm is admixed with a carrier capable of adjusting the pH of the composition to a pH range of from 6.1 to 7.0.

12. (Previously presented) The method of claim 11 wherein the agent is an acid having its dissociation constant in a range of from 6.7 to 7.4.

13. (Previously presented) The method of claim 12, wherein said dissociation constant is in a range of from 6.9 to 7.3

14. (Previously presented) The method of claim 13, wherein said dissociation constant is about 7.0.

15. (Previously presented) The method of claim 11, wherein said agent is cis-urocanic acid and wherein the carrier is able to adjust the pH of the composition to 6.5 to 7.0.

16. (Currently amended) A method ~~of~~ for treatment or prevention of a disease or disorder curable by immunosuppression, comprising

administering to a person or animal in need ~~of said treatment~~ thereof a pharmaceutical composition ~~produced by the method of claim 11~~ comprising a pharmaceutically acceptable agent or salt thereof capable of acidifying cell cytoplasm,

wherein an effective amount of said agent is administered in an essentially non-dissociated form to said person or animal, and

wherein said agent is mixed with a carrier to adjust the pH of said composition to a pH range of 6.1 to 7.0.

17. (Previously presented) The method of claim 16, wherein the disease or disorder is a member of the group consisting of a local

inflammatory disease, a systemic inflammatory disease, an autoimmune disease and an allergic condition.

18. (Previously presented) The method of claim 17 wherein the disease or disorder is a local or systemic inflammatory reaction.

19. (Previously presented) The method of claim 18, wherein said reaction involves activation of cells of innate immune system.

20. (Previously presented) The method of claim 19, wherein said reaction is a member of the group consisting of contact hypersensitivity reactions, delayed type hypersensitivity reactions, acute graft rejection, psoriasis, dermatitis, periodontitis, mastitis, and vasculitis.

21. (Previously presented) The method of claim 16, wherein the agent is administered systemically or locally.

22. (Previously presented) The method of claim 21, where said agent is administered topically.

23. (Previously presented) A pharmaceutical composition comprising as active agent a pharmaceutically acceptable agent or salt thereof being able to acidify the cell cytoplasm, in combination with a pharmaceutically acceptable carrier, which carrier essentially prevents the agent from dissociating at extracellular pH values and wherein the carrier is able to keep the pH of the composition in a range of from 6.1 to 7.0.

24. (Previously presented) The composition of claim 23 wherein said agent is an acid having a dissociation constant in a range of from 6.7 to 7.4.

25. (Previously presented) The composition of claim 24, wherein said dissociation constant is in a range of from 6.9 to 7.3.

26. (Previously presented) The composition of claim 25, wherein dissociation constant is about 7.0.

27. (Previously presented) The composition of claim 23, wherein said agent is cis-urocanic acid and wherein the carrier is able to keep the pH of the composition in a range of from 6.5 to 7.0.